Functions of CD28, CTLA-4 and PD-1
Abstract
2018 is time in between since immunotherapies are recognized as treatments in cancer even in patients where they were supposed to be not or poorly active. We will focus on a review on facts meaning data reproduced during the last thirty-five years and what they have provided. We will focus on these data and question them regarding the novel and unexpected clinical that were not anticipated by the preclinical data. Consequently we will mainly present data regarding CD28,CTLA-4PD-1 and their ligands. We will not address the complex network of proteins involved in cosignalling in tissues.